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Background: Syncytial giant cell hepatitis (GCH) is an uncommon and an underreported disease entity. In two
previously reported cases of GCH in patients with Chronic Lymphocytic Leukemia (CLL) liver failure ensued.
Autoimmune and infective causes have been implicated but its etiology remains unclear.
Case Presentation: A 60-year-old female with CLL presented with acute hepatitis with negative viral and
auto-immune serologies and without any prior toxic exposure. Liver biopsy showed typical histological features of
GCH. The patient was successfully treated with corticosteroids and intravenous immunoglobulin (IVIG). Her liver
enzymes returned to baseline and have remained normal as of the last follow up almost 4 years later.
Conclusions: Association of GCH with CLL may be under recognized. Clinical suspicion of GCH in CLL patients with
serology-negative hepatitis, early liver biopsy and therapeutic intervention may influence outcome. This is the first
case report of successful treatment of GCH in CLL patients. Moreover, our case also demonstrates the ability to
resume effective CLL therapy post-GCH diagnosis without detriment to the liver.Background
Syncytial giant cell hepatitis (GCH) was first described
by Phillips in 1991 [1]. This is an uncommon and often
fulminant form of hepatitis characterized histologically
by diffuse giant cell transformation of hepatocytes.
GCH is a rare condition found in 0.25% of liver biop-
sies in one study [2]. Giant cell transformation has been
described in association with a number of diseases such
as autoimmune hepatitis [3] with or without primary
sclerosing cholangitis [4], paramyxovirus (measles) virus
[1,5], herpes group of viruses [6], and hepatitis C [7]. In
another series GCH was reported in 0.6% of liver biop-
sies done in patients with HIV [8,9]. There have been
two separate case reports in the literature of GCH in
patients with chronic lymphocytic leukemia (CLL). Fim-
mel et al. [5] reported GCH in a patient with CLL who
progressed to cirrhosis. Alexpoulou [10] in 2003
reported a fatal case of GCH in a patient with CLL.
In this report, we describe a patient with CLL who
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reproduction in any medium, provided the orsteroids and intravenous immunoglobulin (IVIG) along
with her follow up for four years after the episode. This
case suggests that early recognition, diagnosis and treat-
ment of GCH in CLL patients may lead to favorable
outcome.Case presentation
Our patient is a 60 year-old female with history of Rai
stage II chronic lymphocytic leukemia (CLL) which was
diagnosed in January 2004. She did well without treat-
ment till August 2006. In August 2007, she presented
with sudden onset of nausea, vomiting, abdominal pain,
transaminitis and jaundice of 2-month duration. She de-
nied any prior history of jaundice or blood transfusions.
There was no history of travel. She had received 5 cycles
of chemotherapy (oral chlorambucil plus prednisone)
through January 2007. Rituximab was added due to pro-
gression of disease and continued till August 2007. Phys-
ical examination revealed mild icterus, generalized
lymphadenopathy, right upper quadrant tenderness and
splenomegaly without stigmata of chronic liver disease.
Peripheral blood smear revealed marked increase of
small lymphocytes; many smudge cells and normocytic
normochromic RBCs with mild anisocytosis. Serum
acetaminophen and alcohol levels were negative.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Liver Enzymes over disease course.
Figure 3 Giant cells on light microscopy [40x].
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virus, Epstein-Barr virus (EBV), and cytomegalovirus
(CMV) were negative. Hepatitis C PCR was checked for
confirmation and was found to be negative. Auto-
immune workup for anti-nuclear antibody, anti-
mitochondrial antibody, anti-smooth muscle antibody,
anti-liver-kidney-microsomal antibody, and a coombs’
test was negative. Serum ferretin was 1196, iron 163 and
percent saturation was 67.9. Serum copper was within
normal limits. Computerized axial tomography scan of
the abdomen revealed enlarged lymph nodes secondary
to her known CLL but no biliary obstruction.
The patient’s alanine aminotransferase(ALT) peaked
at 2776, aspartate aminotransferase(AST) peaked at
1471, alkaline phosphates at 419 within 9 days of pres-
entation (Figure 1). INR peaked at 1.7. Liver biopsy
was done which revealed syncytial giant cell hepatitis
(GCH) with extensive periportal and subsinusoidal fi-
brosis along with infiltration by small lymphocytes
(Figures 2, 3, 4 and 5).Figure 2 Giant cell hepatitis- light microscopy [10x].The patient was treated with hydrocortisone 100 mg
every eight hours for 9 days and intravenous immuno-
globulin 1gm/kg body weight once every 4 weeks. She
was discharged on oral prednisone 60 mg/day.
Post-discharge at day 36 after presentation her liver
enzymes normalized (Figure 1). Patient’s CLL treatment
was changed to a fludarabine (25 mg/m2 daily for 5
consecutive days), plus monthly rituximab (375 mg/m2
on day 1) and IVIG (1gm/kg BW) without signs of
hepatitis. The patient developed warm antibody auto-
immune hemolytic anemia (AIHA) in April 2008 with
positive coombs test. Due to AIHA, fludarabine wasFigure 4 CD 5 immunostain.
Figure 5 CD79a immunostain.
Table 1 Laboratory studies obtained at initial
presentation
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monthly rituximab was continued. Her CLL therapy
was changed in May 2011 to Bendamustine (90 mg/m2/
day for 2 days in a row) with rituximab (375 mg/m2 IV
on day 1). The patient has received 2 cycles as of July
2011 and has shown significant reduction in her spleno-
megaly, lymphadenopathy and her lymphocytosis. As of
the last follow up in July 2011 her liver enzymes have
remained normal. Treatment is fairly well tolerated al-




Hemoglobin (gm/dL) 12.3 12-16
WBC count (/uL) 237,800 3,500-10,000
Lymphocytes (%) 92
Platelet Count (/uL) 233,000 150,000-350,000
Total Bilirubin (mg/dL) 4.2 0.3-1.2
Direct Bilirubin (mg/dL) 2.9 0-0.3
Alkaline Phosphatase (Units/L) 366 20-125
ALT (Units/L) 2070 0-35
AST (Units/L) 815 0-35
Total Protein (gm/dL) 5.4 6-7.8
Albumin (gm/dL) 4.1 3.5-5.5
Total Globulin (gm/dL) 1.3 2.5-3.5
LDH (Units/L) 547 40-100
INR 1.5
Coombs’ Test Negative
Serum IgG (mg/dL) 493 751-1560
Serum IgA (mg/dL) 43 82-453
Serum IgM (mg/dL) 26 46-304Discussion
GCH is a rare disorder that presents as acute hepatitis.
It is characterized histologically by the presence of syn-
cytial giant cells. Two major hypotheses proposing in-
fective and autoimmune etiologies have been considered
[6,11]. Its association with CLL was noted previously in
two published reports. Fimmel et al. in 1998 published
the first case of GCH in a patient with CLL [5]. There
are significant differences between our case and that
reported by Fimmel et al.. CLL was concurrently diag-
nosed with GCH in Fimmel’s report in a patient with
normal immunoglobulin levels. In contrast, our patient
had an established diagnosis of CLL with hypogamma-
globulinemia, and was on chemotherapy. In Fimmel’s
case, the patient progressed to cirrhosis within one year
of presentation. In our case early diagnosis and treat-
ment has favorably influenced the course of liver disease.
In the second case reported by Alexpoulou [10], a diag-
nosis of GCH was made only at post-mortem examin-
ation of the liver since the diagnosis was not suspected
ante-mortem.Similar to its etiology, the best treatment approach for
GCH is also not clear. Variety of therapeutic interven-
tions has been reported in the literature [6,8,11,12]. The
most commonly used agents are corticosteroids with
varying results. Pegylated interferon alpha-2b was used
with ribavirin in a case of GCH associated with HIV in-
fection with good results [8]. None of these therapeutic
interventions, however, is consistently beneficial [9,13].
Patients with fulminant liver failure or late cirrhotic
stages are usually treated with liver transplantation
[6,11]. It is interesting however that disease was reported
to recur in the transplanted liver [14].
GCH in patients with CLL presents special challenges
to diagnose and treat. Detection of viral DNA by poly-
merase chain reaction (PCR) technique is highly recom-
mended to definitively rule out viral etiologies. Also the
immune compromised condition of CLL patients
whether disease- or treatment-related can make viral
serology studies unreliable. After excluding known
causes of acute hepatitis, GCH should be suspected.
GCH is a pathological diagnosis and liver biopsy should
be performed. Electron microscopy should be routinely
included in the planning of liver biopsy since biopsy ma-
terial may not be adequate for subsequent testing.
In deciding on how to best treat GCH in CLL patients,
several factors related to the underlying CLL should be
taken into consideration. In our case, the finding of
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CLL is a disease known to be associated with hypogam-
maglobulinemia in up to 30% of the cases and where
IVIG is beneficial as adjunct in the management of in-
fectious complications [15,16]. Our patient was also
treated with steroids, which have been commonly used
in GCH [13] and are useful in CLL [17]. With the devel-
opment of Coomb’s-positive autoimmune hemolytic
anemia (AIHA), treatment was switched to oral cyclo-
phosphamide and rituximab to avoid exacerbation of
AIHA by fludarabine. Evidence supporting the use of
cyclophosphamide and rituximab is present in the
pediatric age group for the treatment of GCH [12] and
the same regimen was used successfully in the treatment
of fludarabine-associated AIHA in CLL [18].
Conclusions
In conclusion, our case brings to attention the associ-
ation between CLL and GCH. High index of suspicion is
required in serology-negative acute hepatitis in patients
with CLL. In contrast to similar cases reported by Fim-
mel and Alexpoulous where the disease either pro-
gressed to cirrhosis or fulminant hepatic failure, our
patient responded well to therapy and was able to re-
sume treatment for CLL. While there is no evidence to
date demonstrating increased risk of CLL patients to
GCH, the host environment in CLL is conducive of
GCH, i.e. association with auto antibodies and suscepti-
bility to infections. Recognizing such cases is crucial to
the development of suitable therapeutic strategies.
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